Servier Pharmaceuticals

Servier employees and their families came together to spend time with one another and enjoy the warm weather during our annual summer outing!     Bringing employees together outside the workplace – and recognizing the families who are part of our community – is one of the ways we foster a strong, people-first culture.     Learn more about life at Servier: https://lnkd.in/gRWqxyj9

#Servier was proud to sponsor and participate in the 2026 National Fragile X Foundation International Fragile X Conference, joining patients, families, advocates, researchers, and healthcare professionals dedicated to advancing understanding and care for those affected by Fragile X syndrome.     We are grateful for the opportunity to listen, learn, and engage with the Fragile X community.    At Servier, our aim is to make a difference in the lives of patients living with difficult-to-treat diseases, and we remain committed to advancing therapies for people impacted by rare neurologic disorders and other areas of high unmet need.    #FragileX #Neurology #RareDisease  

Last week, #Servier proudly supported and participated in two events hosted by the Embassy of France in the United States marking #BastilleDay and 250 years of French-American friendship.      The celebrations highlighted the value of transatlantic collaboration and brought together stakeholders committed to advancing innovation, policy, and patient care.      As a French-founded global pharmaceutical company, we're proud to support partnerships that help advance innovation and improve outcomes for patients around the world. 

Servier’s French roots came alive yesterday as colleagues gathered in our Boston office to cheer on the teams in the World Cup semi-finals.    Win or lose, the match was a great opportunity for employees to come together and share in the excitement!      #Servier #Boston

Today, Servier announced the completion of the acquisition of Edgewise Therapeutics' muscular dystrophy business.   The combination of Edgewise’s expertise in muscular dystrophy with Servier’s global capabilities is a major step forward as we look to accelerate the development of their innovative treatment for people living with Becker and Duchenne.  https://lnkd.in/gU5AyieJ

As Servier continues to grow, we’re looking for a Director, Global Safety Lead to join our Global Safety organization in Boston.     In this role, you’ll lead safety and risk management activities for assigned development and marketed compounds, collaborating with colleagues across the U.S. and France.     As part of a global organization advancing therapies in areas of significant unmet need, you’ll have the opportunity to help shape safety strategies that support patients throughout the treatment journey.     Learn more about the role and apply today: https://lnkd.in/gRWqxyj9 #Servier #Hiring #Careers 

For patients with IDH-mutant low-grade glioma, molecular testing at diagnosis can be a critical step (source: National Library of Medicine (NLM)).     Understanding a tumor’s mutation status helps inform diagnosis and guide more personalized treatment decisions.    That is why at #Servier, we are committed to advancing research and helping unlock possibilities for more personalized glioma care.    Learn more: https://lnkd.in/e_i7mBjD #Glioma #MolecularTesting #PrecisionMedicine 

We are pleased to announce the appointment of Justin Cidado as Head of U.S. Research, expanding his leadership role as Servier continues to advance its oncology pipeline.     Since joining Servier five years ago, Justin has played a critical role in shaping our U.S. Research organization, leading cancer biology and helping drive the identification and progression of new oncology targets.     His leadership has been instrumental in strengthening our scientific foundation, from advancing early research programs to helping integrate and scale our research teams.   Please join us in congratulating Justin on this well-deserved appointment.    Read more here: https://lnkd.in/gSktrewy  

We are pleased to announce the appointment of Justin Cidado as Head of U.S. Research, expanding his leadership role as Servier continues to advance its oncology pipeline.     Since joining Servier five years ago, Justin has played a critical role in shaping our U.S. Research organization, leading cancer biology and helping drive the identification and progression of new oncology targets.     His leadership has been instrumental in strengthening our scientific foundation, from advancing early research programs to helping integrate and scale our research teams.  Please join us in congratulating Justin on this well-deserved appointment.    Read more here: https://lnkd.in/gSktrewy

When a child is diagnosed with pediatric low-grade glioma (pLGG), caregivers rely on guidance from physicians to help them navigate their child’s diagnosis and treatment. We presented results from a survey of pLGG caregivers at #ISPNO2026 that unveils challenges and opportunities to help improve caregiver-physician communication.